Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Throughout the last three months, 7 analysts have evaluated DocGo (NASDAQ:DCGO), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 6 | 1 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 2 | 0 | 0 | 0 | 0 |
2M Ago | 3 | 1 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for DocGo, revealing an average target of $10.0, a high estimate of $11.00, and a low estimate of $8.00. A decline of 16.67% from the prior average price target is evident in the current average.
In examining recent analyst actions, we gain insights into how financial experts perceive DocGo. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Richard Close | Canaccord Genuity | Lowers | Buy | $9.00 | $10.00 |
David Grossman | Stifel | Lowers | Buy | $8.00 | $11.00 |
David Larsen | BTIG | Lowers | Buy | $11.00 | $13.00 |
Sarah James | Cantor Fitzgerald | Lowers | Overweight | $11.00 | $13.00 |
Richard Close | Canaccord Genuity | Lowers | Buy | $10.00 | $11.00 |
Ryan MacDonald | Needham | Lowers | Buy | $10.00 | $14.00 |
David Grossman | Stifel | Lowers | Buy | $11.00 | $12.00 |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of DocGo's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on DocGo analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: DocGo displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 83.16%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: DocGo's net margin excels beyond industry benchmarks, reaching 3.8%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): DocGo's ROE stands out, surpassing industry averages. With an impressive ROE of 2.57%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.66%, the company showcases effective utilization of assets.
Debt Management: DocGo's debt-to-equity ratio is below the industry average. With a ratio of 0.15, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: DCGO